Literature DB >> 32075762

OTULIN Prevents Liver Inflammation and Hepatocellular Carcinoma by Inhibiting FADD- and RIPK1 Kinase-Mediated Hepatocyte Apoptosis.

Lien Verboom1, Arne Martens1, Dario Priem1, Esther Hoste1, Mozes Sze1, Hanna Vikkula1, Lisette Van Hove1, Sofie Voet1, Jana Roels2, Jonathan Maelfait1, Laura Bongiovanni3, Alain de Bruin3, Charlotte L Scott1, Yvan Saeys2, Manolis Pasparakis4, Mathieu J M Bertrand1, Geert van Loo5.   

Abstract

Inflammatory signaling pathways are tightly regulated to avoid chronic inflammation and the development of disease. OTULIN is a deubiquitinating enzyme that controls inflammation by cleaving linear ubiquitin chains generated by the linear ubiquitin chain assembly complex. Here, we show that ablation of OTULIN in liver parenchymal cells in mice causes severe liver disease which is characterized by liver inflammation, hepatocyte apoptosis, and compensatory hepatocyte proliferation, leading to steatohepatitis, fibrosis, and hepatocellular carcinoma (HCC). Genetic ablation of Fas-associated death domain (FADD) completely rescues and knockin expression of kinase inactive receptor-interacting protein kinase 1 (RIPK1) significantly protects mice from developing liver disease, demonstrating that apoptosis of OTULIN-deficient hepatocytes triggers disease pathogenesis in this model. Finally, we demonstrate that type I interferons contribute to disease in hepatocyte-specific OTULIN-deficient mice. Our study reveals the critical importance of OTULIN in protecting hepatocytes from death, thereby preventing the development of chronic liver inflammation and HCC.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32075762     DOI: 10.1016/j.celrep.2020.01.028

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  15 in total

Review 1.  Tumor-intrinsic and immune modulatory roles of receptor-interacting protein kinases.

Authors:  A Justin Rucker; Francis Ka-Ming Chan
Journal:  Trends Biochem Sci       Date:  2022-01-05       Impact factor: 13.807

Review 2.  The regulation of necroptosis by ubiquitylation.

Authors:  Yiliang Chen; Wenqing Ren; Qingsong Wang; Yuan He; Dan Ma; Zhenyu Cai
Journal:  Apoptosis       Date:  2022-08-08       Impact factor: 5.561

Review 3.  Deubiquitinases in cell death and inflammation.

Authors:  Kim Newton; Alexander D Gitlin
Journal:  Biochem J       Date:  2022-05-27       Impact factor: 3.766

Review 4.  Met1-linked ubiquitin signalling in health and disease: inflammation, immunity, cancer, and beyond.

Authors:  Akhee Sabiha Jahan; Camilla Reiter Elbæk; Rune Busk Damgaard
Journal:  Cell Death Differ       Date:  2021-01-13       Impact factor: 12.067

Review 5.  Linear Ubiquitin Code: Its Writer, Erasers, Decoders, Inhibitors, and Implications in Disorders.

Authors:  Daisuke Oikawa; Yusuke Sato; Hidefumi Ito; Fuminori Tokunaga
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

6.  OTULIN is a new target of EA treatment in the alleviation of brain injury and glial cell activation via suppression of the NF-κB signalling pathway in acute ischaemic stroke rats.

Authors:  Hongbei Xu; You Wang; Yong Luo
Journal:  Mol Med       Date:  2021-04-09       Impact factor: 6.354

Review 7.  Molecular Mechanisms of DUBs Regulation in Signaling and Disease.

Authors:  Ying Li; David Reverter
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

8.  Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases.

Authors:  Yun Seok Kim; Sang Geon Kim
Journal:  Clin Mol Hepatol       Date:  2020-09-22

Review 9.  Ubiquitin-dependent and -independent functions of OTULIN in cell fate control and beyond.

Authors:  Nadine Weinelt; Sjoerd J L van Wijk
Journal:  Cell Death Differ       Date:  2020-12-07       Impact factor: 12.067

Review 10.  The Met1-linked ubiquitin machinery in inflammation and infection.

Authors:  Berthe Katrine Fiil; Mads Gyrd-Hansen
Journal:  Cell Death Differ       Date:  2021-01-20       Impact factor: 12.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.